Tag: pembrolizumab

Results from a global Phase 3 trial demonstrated that trastuzumab deruxtecan (T-DXd; Enhertu®; Daiichi Sankyo and AstraZeneca) can delay disease progression longer than standard...

Triple-negative breast cancer (TNBC) remains one of the most challenging and most malignant subtypes of breast cancer to treat. TNBC represents a heterogeneous group...

Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer: Topline Results from the Phase 3 SigVie-002 Study

Phase 3 Study Supports Sacituzumab Govitecan + Pembrolizumab as a Potential New Standard of Care in First-line PD-L1+ mTNBC

ESMO 2025: Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care

The Phase 3 EV-303 is an ongoing clinical trial evaluating enfortumab vedotin (Padcev™; Pfizer and Astellas Pharma), a Nectin-4 directed antibody-drug conjugate (ADC), in combination with pembrolizumab (Keytruda™; Merck & Co), a PD-1 inhibitor, as neoadjuvant and adjuvant treatment (before and after surgery) versus surgery alone, the current standard of care, in patients with muscle-invasive bladder cancer (MIBC) who are not eligible for or declined cisplatin-based chemotherapy.

The combination of sacituzumab govitecan (Trodelvy®; Gilead Sciences; See ADC Drugmap)* + pembrolizumab (Keytruda®; Merck & Co/MSD) reduced the risk of disease progression or death by 35% (HR: 0.65) versus standard of care (SoC) pembrolizumab plus chemotherapy in first-line treatment for patients with PD-L1+ (CPS ≥10) metastatic triple-negative breast cancer (TNBC).

During the upcoming annual meeting of the American Society of Clinical Oncology (ASCO) which will take place May 30 – June 3, 2025, in Chicago, Illinois, Rakuten Medical* will be presenting a Trial in Progress poster with updates of the company's ongoing global Phase 3 clinical trial evaluating ASP-1929 photoimmunotherapy in combination with the anti-PD-1 pembrolizumab (Keytruda®; Merck & Co / MSD) as a first-line therapy for patients with recurrent head and neck squamous cell carcinoma (HNSCC).

China Approves Combination of Enfortumab Vedotin + Pembrolizumab for the Treatment of Advanced Bladder Cancer

During the upcoming European Society for Medical Oncology (ESMO) Congress 2024, being held September 13-17, 2024 in Barcelona, Spain, Pfizer is presenting encouraging early results for preliminary efficacy and safety data for disitamab vedotin* in combination with pembrolizumab (Keytruda®; Merck & Co), and results from an additional analysis from the pivotal EV-302 trial supporting the combination of enfortumab vedotin (Padcev®; Astellas/Pfizer) and pembrolizumab (Keytruda®; Merck & Co) as a new standard of care for patients with previously untreated la/mUC.